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Transient osteoporosis of the hip (TOH) is a rare disorder of unknown etiology that is characterized by acute onset 
of disabling bone pain. The locally increased bone turnover and low bone mineral density (BMD) associated 
with this disorder indicate a potential role for an antiresorptive agent such as bisphosphonate as a treatment. A 
previously healthy 46-year-old man developed the sudden onset of pain in his right buttock and inguinal area, 
especially during walking and caused him to limp. A thorough medical workup including X-ray, MRI, and bone 
SPECT revealed transient osteoporosis of the hip, and he was treated with an infusion of zoledronate (5 mg). Two 
weeks later, he was fully recovered from pain and the gait disturbance. A follow-up MRI of the hip joint taken after 
6 months showed complete resolution. Th   e use of intravenous zoledronate provided a successful outcome in the 
treatment of TOH. Th   e possibility of TOH should be considered in patients complaining of sudden hip pain and 
a limping gait. MR imaging played an important role for diff  erentiation of TOH from other aggressive conditions 
with long term sequelae.
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trimester of pregnancy. In most cases, it is spontaneously 
resolved by conservative treatments such as limited 
weight bearing and conservative therapies within 6-12 
months, or sometimes within 24 months.
1 The authors 
used intravenous infusion of zoledronate for one patient 
diagnosed with transient osteoporosis of the hip, and 
obtained effective reduction of disease duration and 
pain. Accordingly, this case is reported with a review of 
relevant references. 
 
CASE REPORT
  A male patient aged 46 years old visited the hospital due 
to pain in the right buttock and the inguinal area while 
standing up from a chair. Under the suspected condition 
INTRODUCTION
  
  Transient osteoporosis of the hip, a rare clinical synd-
rome whose causes are unknown, shows transient oste-
openia and rapid or gradual progression of pain, leading 
to maximum functional disability within 4-8 weeks, 
followed by subsequent improvement. In particular, it 
occurs in middle-aged males, and females in their third 
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of bursitis of the hip, nabumetone (1,000 mg/day) was 
orally administered to the patient for 2 weeks. However, 
the pain was not relieved and the symptoms deteriorated 
upon weight bearing. Th   e patient experienced a limping 
gait 10 days after symptom expression and depended on a 
wheelchair. Th   e patient had no previous history of trauma 
and had been taking medication due to hypertension 
for 5 years. Th   e patient was relatively healthy except for 
smoking one pack of cigarettes a day and drinking 3 times 
a week. During a physical examination conducted upon 
hospitalization 2 weeks after expression of symptoms, 
no muscle weakness of the bilateral lower extremities 
was observed in manual muscle testing (MMT). Limited 
range of motion of the right hip joint due to pain, a 
positive right Patrick sign, and pain in the right inguinal 
area and the buttock were observed. Meanwhile, normal 
findings were observed in the deep tendon reflex of the 
lower extremities and the straight leg raising test. In 
hematologic tests, erythrocyte sedimentation rate was 
11 mm/hr (normal range, 0-22), and C-reactive protein 
was 0.62 mg/dl (normal range, 0.00-0.50). When hip 
joint MRI was performed, the joint space of the bilateral 
hip was shown to be maintained, and a lesion, which 
showed patch low signal intensity with unclear border 
in a T1 weighted image and non-homogeneous high 
signal intensity in a T2 weighted image, was found across 
the right femoral head and neck (Fig. 1). In addition, 
the joint surface of the femoral head was shown to be 
maintained, and no circular band of the bone marrow 
of the femoral head, which is shown in avascular 
necrosis, was found. In a bone scan test, avascular 
necrosis was ruled out due to the increased uptake of 
radioisotopes in the bone marrow of the femoral head. 
After being diagnosed with transient osteoporosis of the 
hip, nabumetone administration (1,000 mg/day for 15 
days) was discontinued. Subsequently, a single dose of 
zoledronate (5 mg) was intravenously infused for more 
than 15 minutes. Weight bearing was minimized by 
using crutches and a wheelchair. Hot pack, ultrasound, 
and interferential current therapies were performed on 
the hip. Normal gait was achieved one week after the 
treatments. No pain was observed upon weight bearing 
despite a slight pain in the inguinal area 2 weeks after 
treatments. However, the patient was asked to use 
crutches for an additional 2 weeks to minimize weight 
bearing on the hip joint. No pain in the inguinal area and 
Fig. 1. (A) The coronal T1 weighted 
image of hip joint shows patchy 
low signal intensity lesion in right 
femoral head (arrow), (B) which 
demonstrates high signal intensity 
lesion on fat suppressed coronal T2 
weighted image (arrow).
Fig. 2. Follow-up hip MRI showed 
no abnormal lesion in both femoral 
heads.Hyun Seok, et al.
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no pain in the hip joint upon weight bearing were shown 
4 weeks after treatments. When MRI was taken 6 months 
later, previous abnormal findings were completely 
resolved and no clinical recurrence was found (Fig. 2).
DISCUSSION 
  Transient osteoporosis of the hip rarely occurs, but 
causes pain independent from trauma, and increases 
bone turnover.
2 Due to diffi   culty of early diagnosis caused 
by rareness and normal early radiological fi  ndings, TOH 
is often overlooked.
3 So far, approximately 300 cases 
have been reported. Despite controversy about the 
causes and pathophysiology of the disease, it has been 
generally accepted that transient osteoporosis of the hip 
is a self-limiting disease. It is spontaneously resolved by 
conservative treatments such as limited weight bearing 
and analgesic treatment within 6-24 months. Restoration 
of bone density and normal MRI are achieved within 
6-12 months.
4,5 Due to its non-specific symptoms and 
signs, distinguishing TOH from avascular necrosis or 
other inflammatory or neoplastic diseases is difficult, 
but bone marrow edema observed in MRI is useful for 
early diagnosis and discrimination.
6 Characteristic 
MRI findings include a diffuse low signal intensity in 
a T1 weighted image, and high signal intensity in a T2 
weighted image. Th   ese types of MRI fi  ndings decrease as 
the symptoms improve. Discrimination is possible due 
to the lack of a low signal intensity band in a T1 weighted 
image, or a double line sign in a T2 weighted image, 
which are shown in avascular necrosis.
7,8
  For treatment of transient osteoporosis of the hip, 
conventional managements such as limited weight 
bearing and analgesic treatment have been mainly 
applied, but various other treatments have recently 
been performed to shorten the clinical course of the 
disease. Among such treatments, bisphosphonate 
has been reported to be successfully used to treat the 
disease by strongly inhibiting bone turnover, because 
its efficacy for other metabolic bone diseases has been 
proven.
3,9 Although the mechanism via which bone 
pain is effectively reduced remains unknown, pain 
reduction is likely to be attributable to the resolution of 
fundamental causes and the anti-infl  ammatory property 
of bisphosphonate, considering the drug has no analgesic 
eff  ect involved in its mechanism.
2 Transient osteoporosis 
of the hip shows increased bone turnover and bone loss 
due to increased bony destructive activities, resulting 
in the deterioration of the stability of bone structure. 
This result causes gradual weakness, torsion, and pain 
at the bone. It is expected that bisphosphonate, which 
is intravenously administered to treat such conditions, 
reduces increased bony destructive activities and rapidly 
restores bone, resulting in concurrent pain reduction. 
Varrena et al.
3 reported that symptoms were resolved 
in 15 patients two months after intravenous injection 
of pamidronate, and normal findings were shown in 
MRI three months after injection. Ringe et al.
2 reported 
that symptoms improved in 12 patients one month 
after intravenous injection of ibandronate. Accordingly, 
the authors administered zoledronate, one of the 
bisphosphonate class of drugs that is administered once 
a year. As a result, the patient’s symptoms were almost 
resolved two weeks after treatment, suggesting that this 
treatment might be more effective in reducing disease 
duration compared with those mentioned in previous 
studies. Therefore, transient osteoporosis of the hip is 
necessary to be considered in middle-aged male patients 
suffering from hip joint pain and gait disturbance as 
a differential diagnosis from other diseases leaving 
long-lasting sequelae, such as avascular necrosis of 
the femoral head and joint destructive diseases due to 
joint infl  ammation and tumor.
10 In the cases of transient 
osteoporosis diagnosed using MRI or bone scanning, 
invasive diagnosis or treatment is unnecessary, and 
intravenous injection of bisphosphonate such as 
zoledronate, rather than anti-infl  ammatory drugs, could 
be safer and more eff  ective.
  Th   is case report has the limitation that follow-up using 
MRI was not conducted earlier than 6 months, which is 
a reported time point for the initiation of spontaneous 
resolution. However, it is meaningful because the 
complete resolution of the lesion was observed; a result 
not previously reported in Korea. Additionally, faster 
recovery was observed in patients who had more severe 
symptoms than those reported in foreign patients. The 
authors obtained an effective reduction of pain and 
disease duration by intravenously injecting zoledronate 
into the patients who suffered from inguinal and 
femoral pain, and who were diagnosed with transient 
osteoporosis of the hip by MRI. Accordingly, this case is 
reported herein.Treatment of Transient Osteoporosis of the Hip with Intravenous Zoledronate
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